CervoMed (CRVO) reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, SVP, Medical Science in October 2024. Additionally, Mark De Rosch, Ph.D., FRAPS, recently joined CervoMed as Senior Vice President, Regulatory and Government Affairs and Program Management.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: